CA
NZ
UK
AU
IND
US
Non-GAAP gross margin was 58.7%, reflecting a favorable mix of products. The CEO said EBITDA grew 7% and non-GAAP EPS was up 10%, at USD 0.86. GAAP net profit was USD 233 million, or USD 0.20 per share.
Total locations increased 21% to 189,000, and gross paymentVolumeincreased 20% to USD 61.8 billion.Gross Profitfrom subscription services and financial technology solutions grew 29% to USD 630 million, and the non-GAAP measure of that gross profit grew 27% to USD 642 million. Chief Executive Officer …
The net loss was USD 31.4 million, compared with USD 41.9 million in the prior-year quarter. Net loss per common share was USD 0.88, compared with USD 1.50, on 35.7 million weighted-average shares versus 27.8 million. The company has not reported revenue.
Insurance segment revenue was USD 234.9 million, up 15%, with segment profit of USD 54.2 million, up 14%. Consumer segment revenue was USD 67.2 million, up 2%, while segment profit of USD 29.6 million declined 16%. Home segment revenue was USD 41.5 million, up …
Service revenue was USD 64.8 million versus USD 52.8 million. It included USD 3.5 million of incremental revenue from the acquisitions of Essco, SCM and Southeastern, and service organic revenue increased 15.8%. The company cites high customer retention andDemandin life sciences, aerospace and defense, …
Total expenses were USD 56.7 million versus USD 57.7 million. Interest expense was USD 30.5 million versus USD 31.4 million, management fees were USD 13.3 million versus USD 13.1 million, and incentive fees on net investment income were USD 8.8 million versus USD 10.5 …
Net written premium rose 13.2% to USD 371.4 million, and netEarned Premiumrose 10.4% to USD 362.5 million. The company said growth was led by its core commercial business. Core commercial average renewal premium increased 3.0%, made up of rate increases of 2.0% and exposure …
President and Chief Executive Officer Mitch Rock said MedTech sales grew 12.5% and that adjusted operating income grew 14.5%. For the nine months, net sales were USD 500.6 million versus USD 453.9 million, organic growth was 7.9%, MedTech sales grew 11.7% and the top …
The results also include a net tax-only benefit of USD 12.0 million, reflecting the release of an unrecognized tax benefitLiabilityof USD 188.2 million, mostly offset by a deferred tax asset valuation allowance of USD 176.2 million. After-tax adjusted operating income was USD 349.0 million, …
Adjusted EBITDA was USD 12.1 million, compared with USD 13.8 million, a decrease of 13% year over year and 44% sequentially. The figures exclude the noncontrolling interest of 21.2% in Hiya.
Please wait processing your request...